Aiyada Aroonsri

Dr. Aiyada Aroonsri

National Center for Genetic Engineering and Biotechnology, Pathum Thani, Thailand
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2014 in Molecular and Biochemical Parasitology
Verified
Journal Article
Closed access
CWChayaphat Wongsombat
Chayaphat Wongsombat
Aiyada AroonsriAiyada Aroonsri
Aiyada Aroonsri
SKSumalee Kamchonwongpaisan
Sumalee Kamchonwongpaisan
HMHugh P. Morgan
Hugh P. Morgan
MWMalcolm Walkinshaw
Malcolm Walkinshaw
PSPhilip J. Shaw
Philip J. Shaw

1 April 2022 in Current Pharmaceutical Biotechnology
Verified
Journal Article
Closed access
PDF file
Ya'u Sabo AjingiYa'u Sabo Ajingi
Ya'u Sabo Ajingi
NRNeeranuch Rukying
Neeranuch Rukying
Aiyada AroonsriAiyada Aroonsri
Aiyada Aroonsri
NJNujarin Jongruja
Nujarin Jongruja
Recombinant active peptides are utilized as diagnostic and biotherapeutics in various maladies and as bacterial growth inhibitors in the food industry. This consequently stimulated the need for recombinant peptides' production, which resulted in about 19 approved biotech peptides of 1-100 amino acids commercially available. While most peptides have been produced by chemical synthesis, the production of lengthy and complicated peptides comprising natural amino acids has been problematic with low quantity. Recombinant peptide production has become very vital, cost-effective, simple, environmentally friendly with satisfactory yields. Several reviews have focused on discussing expression systems, advantages, disadvantages, and alternatives strategies. Additionally, the information on the antimicrobial activities and other functions of multiple recombinant peptides is challenging to access and is scattered in literature apart from the food and drug administration (FDA) approved ones. From the reports that come to our knowledge, there is no existing review that offers substantial information on recombinant active peptides developed by researchers and their functions. This review provides an overview of some successfully produced recombinant active peptides of ≤100 amino acids by focusing on their antibacterial, antifungal, antiviral, anticancer, antioxidant, antimalarial, and immune-modulatory functions. It also elucidates their modes of expression that could be adopted and applied in future investigations. We expect that the knowledge available in this review would help researchers involved in recombinant active peptide development for therapeutic uses and other applications.

1 June 2017 in International Journal for Parasitology
Verified
Journal Article
Closed access
PSPhilip J. Shaw
Philip J. Shaw
Aiyada AroonsriAiyada Aroonsri
Aiyada Aroonsri

16 March 2021 in BMC Molecular and Cell Biology
Verified
Journal Article
Open access
PDF file
Aiyada AroonsriAiyada Aroonsri
Aiyada Aroonsri
JKJindaporn Kongsee
Jindaporn Kongsee
JGJeremy David Gunawan
Jeremy David Gunawan
DADaniel Abidin Aubry
Daniel Abidin Aubry
PSPhilip James Shaw
Philip James Shaw
Background: Bioinformatic genome surveys indicate that self-cleaving ribonucleic acids (ribozymes) appear to be widespread among all domains of life, although the functions of only a small number have been validated by biochemical methods. Alternatively, cell-based reporter gene assays can be used to validate ribozyme function. However, reporter activity can be confounded by phenomena unrelated to ribozyme-mediated cleavage of RNA. Results: We established a ribozyme reporter system in Escherichia coli in which a significant reduction of reporter activity is manifest when an active ribozyme sequence is fused to the reporter gene and the expression of a foreign Bacillus subtilis RNaseJ1 5′ exonuclease is induced from a chromosomally-integrated gene in the same cell. Conclusions: The reporter system could be useful for validating ribozyme function in candidate sequences identified from bioinformatics.

1 January 2022 in Molecular and Biochemical Parasitology
Verified
Journal Article
Closed access
CWChayaphat Wongsombat
Chayaphat Wongsombat
YYYodying Yingchutrakul
Yodying Yingchutrakul
NSNattida Suwanakitti
Nattida Suwanakitti
KLKantinan Leetanasaksakul
Kantinan Leetanasaksakul
SRSittiruk Roytrakul
Sittiruk Roytrakul
Aiyada AroonsriAiyada Aroonsri
Aiyada Aroonsri

11 April 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Aiyada AroonsriAiyada Aroonsri
Aiyada Aroonsri
CWChayaphat Wongsombat
Chayaphat Wongsombat
PSPhilip Shaw
Philip Shaw
SFSiegrid Franke
Siegrid Franke
JPJude Marek Przyborski
Jude Marek Przyborski
Annette KaiserAnnette Kaiser
Annette Kaiser
The treatment of a variety of protozoal infections, in particular those causing disabling human diseases, is still hampered by a lack of drugs or increasing resistance to registered drugs. However, in recent years, remarkable progress has been achieved to combat neglected tropical diseases by sequencing the parasites’ genomes or the validation of new targets in the parasites by novel genetic manipulation techniques, leading to loss of function. The novel amino acid hypusine is a posttranslational modification (PTM) that occurs in eukaryotic initiation factor 5A (EIF5A) at a specific lysine residue. This modification occurs by two steps catalyzed by deoxyhypusine synthase (dhs) and deoxyhypusine hydroxylase (DOHH) enzymes. dhs from Plasmodium has been validated as a druggable target by small molecules and reverse genetics. Recently, the synthesis of a series of human dhs inhibitors led to 6-bromo-N-(1H-indol-4yl)-1-benzothiophene-2-carboxamide, a potent allosteric inhibitor with an IC50 value of 0.062 µM. We investigated this allosteric dhs inhibitor in Plasmodium. In vitro P. falciparum growth assays showed weak inhibition activity, with IC50 values of 46.1 µM for the Dd2 strain and 51.5 µM for the 3D7 strain, respectively. The antimalarial activity could not be attributed to the targeting of the Pfdhs gene, as shown by chemogenomic profiling with transgenically modified P. falciparum lines. Moreover, in dose-dependent enzymatic assays with purified recombinant P. falciparum dhs protein, only 45% inhibition was observed at an inhibitor dose of 0.4 µM. These data are in agreement with a homology-modeled Pfdhs, suggesting significant structural differences in the allosteric site between the human and parasite enzymes. Virtual screening of the allosteric database identified candidate ligand binding to novel binding pockets identified in P. falciparum dhs, which might foster the development of parasite-specific inhibitors.